Discovering the Latest from the Blade Therapeutics Phase II Trial

Time: 3:30 pm
day: Day Two


  • Navigating translatability challenges from preclinical models to entering the clinic
  • Designing clinical trials that capture the IPF patient population
  • Uncovering how biomarkers were used effectively as endpoints in the trial
  • Illuminating patient recruitment in a phase II trial